This document acknowledges that the DRIVE project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777363. This joint undertaking receives support from the European Horizon 2020 research and innovation programme and EFPIA. It then lists some public health institutions, universities, and networks in several European countries that are involved in the DRIVE project in 2018/19 and conducts test-negative design studies, cohort studies, and novel innovative studies. Associated partners and research collaborators can receive compensation for participation and retain ownership of their data, while ethics reviews are handled locally. DRIVE accepts individual-level pseudonymised and aggregated/anonymized data.

1. Acknowledgement
DRIVE project has received funding from the Innovative
Medicines Initiative 2 Joint Undertaking under grant
agreement No 777363, This Joint Undertaking receives
support from the European Union’s Horizon 2020
research and innovation programme and EFPIA.
Getting involved in
DRIVE
Acknowledgement
DRIVE project has received funding from the Innovative
Medicines Initiative 2 Joint Undertaking under grant
agreement No 777363, This Joint Undertaking receives
support from the European Union’s Horizon 2020
research and innovation programme and EFPIA.
Topi Turunen, MD
FISABIO-Public Health

2. Sites in 2018/19
PHIs & NICs
• Austria
• Finland
• Italy
• Romania
• Spain-Valencia
• Spain-La Rioja
• [An additional
NPHI]
Universities & networks
• Bambino Gesu
children’s hospital (IT)
• CIRI-IT (IT)
• Helsinki Uni. Central
Hospital (FI)
• Kapodistrian
University of Athens
(GR)
• Uni. Surrey (UK)
• Vall d’Hebron Uni.
Hospital (ES)
• [An European
network]
??

3. Test-negative
design studies
Cohort studies
Novel & innovative
studies

4. Public organizations with
established IVE studies
Other research
organizations
Associate
partners
Research
collaborators
Annual call for tenders
Review by DRIVE SC

5. IVE studies &
sharing data
DRIVE annual
meetings
Scientific
discussion,
publications
Development
of innovative
methodology
Associated Partners and Research Collaborators receive
a compensation for participation in DRIVE activities
They retain the full ownership of their data

6. • Ethics Committee reviews for each study are handled
locally
• Data collection should be compatible with one of the
DRIVE research protocols (with the exception of
innovative studies)
• DRIVE accepts both individual-level pseudonymised
data and aggregated/anonymised data

7. www.drive-eu.org
Acknowledgement
DRIVE project has received funding from the Innovative
Medicines Initiative 2 Joint Undertaking under grant
agreement No 777363, This Joint Undertaking receives
support from the European Union’s Horizon 2020
research and innovation programme and EFPIA.
info@drive-eu.org
@drive_eu